Talent Acquisition Manager

Iterative Health appoints Nadege Gunn, MD, as Chief Medical Officer, Hepatology and Obesity. Provided by Business Wire Feb 12, 2026, 4:50:00 AM Leadership Appointment Solidifies Company's Vested Interest in Advancing Research in Hepatology and Obesity Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the appointment of Nadege Gunn, MD, CPI, DABOM, FAASLD, as Chief Medical Officer, Hepatology and Obesity. Dr. Gunn joins Iterative Health's senior leadership team to provide strategic medical and scientific leadership across metabolic liver disease research and specialized site operations, supporting the company's rapidly expanding hepatology and obesity portfolio. Dr. Nadege Gunn will provide strategic medical and scientific leadership across metabolic liver disease research and specialized site operations, supporting Iterative Health's rapidly expanding hepatology and obesity portfolio. Dr. Gunn is a globally recognized, board-certified gastroenterologist, hepatologist, obesity medicine specialist, and physician-scientist with more than 15 years of experience as a principal investigator on over 100 early- and late-phase clinical trials. Her research expertise spans metabolic and the spectrum of liver disease, including MASH and MASLD, with a proven track record of translating complex protocols into high-performing, community-based research programs. At Iterative Health, Dr. Gunn will lead the advancement of hepatology and obesity research by overseeing medical affairs, development of specialized site operations, and strategic collaboration with biopharmaceutical sponsors and CRO partners. Her appointment underscores Iterative Health's commitment to building a leading, performance-driven research site network that expands access to innovative multispecialty therapies, while accelerating novel therapies to market faster. "Iterative Health has created an impressive foundation to advance hepatology and obesity research at scale," said Dr. Gunn. "As a practicing physician and with experience as a principal investigator, I'm excited to join a team that is deeply focused on empowering providers and extending cutting-edge clinical research into the communities that care for these patients every day." Dr. Gunn currently practices at Coryell Health, a rural community-based practice, and serves as the hepatology clinic director. She brings more than 15 years of leadership experience across clinical research operations, peer-to-peer education, and international protocol development. She is the founder and former President and CEO of Impact Research Institute in Waco, Texas, widely regarded as one of the nation's leading hepatology research centers. In addition, Dr. Gunn has held academic teaching appointments at Texas A&M University, Dell Medical School at The University of Texas at Austin, and Baylor University. Within the Chronic Liver Disease Foundation (CLDF), Dr. Gunn also serves as a key committee member of the Women in Hepatology: Initiatives, Sponsorship, and Empowerment (WHISE), dedicated to enhancing visibility and opportunities for women in the field. Dr. Gunn's appointment reflects Iterative Health's continued investment in strategic leadership and the expansion of its therapeutic focus areas. As part of this leadership growth, Iterative Health also announced the promotion of Dana Feuchtbaum from Chief Product Officer to Chief Operating Officer. In this role, Feuchtbaum will oversee operations and technology development, empowering Iterative Health's global site network spanning four continents. "For providers and sponsors alike, Dr. Gunn strengthens the clinical leadership and operational confidence behind every hepatology and obesity study we support," said Dana Feuchtbaum, Chief Operating Officer at Iterative Health. "Her appointment accelerates our ability to support increasingly complex hepatology and obesity trials at scale." About Iterative Health Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. The company has headquarters in Cambridge, Massachusetts, and New York, New York. For more information, visit www.iterative.health and follow us on LinkedIn for the latest company updates. Media Contact Iterative Health: Andrea Sampson Sampson Public Relations Group [email protected] The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar. Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees. Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Iterative Health adds Nadege Gunn as CMO, Hepatology and Obesity. Gunn will provide medical and scientific leadership across metabolic liver disease research and specialized site operations. February 12, 2026 Content Marketing Editor Iterative Health has hired Nadege Gunn, MD, as Chief Medical Officer (CMO), Hepatology and Obesity. Gunn currently practices at Texas-based Coryell Health, serving there as hepatology clinic director. She is the founder, and former president and CEO, of the hepatology-focused Impact Research Institute in Waco, Texas. Role of new CMO. Gunn's appointment to the Iterative Health team serves to provide strategic medical and scientific leadership in metabolic liver disease research. Gunn will also oversee specialized site operations to support Iterative Health's expanding hepatology and obesity portfolio. By strategically collaborating with biopharmaceutical sponsors and contract research organization (CRO) partners, Gunn will impact future plans for Iterative Health. These include creating a performance-driven network of research sites expanding access to multispecialty therapies, and accelerating novel therapies to market. Other Iterative Health moves. Iterative Health is also promoting Dana Feuchtbaum from Chief Product Officer to Chief Operating Officer. Feuchtbaum said that Gunn joining the team will benefit providers and sponsors alike. "Gunn strengthens the clinical leadership and operational confidence behind every hepatology and obesity study we support," Feuchtbaum said. "Her appointment accelerates our ability to support increasingly complex hepatology and obesity trials at scale." Prior Gunn experience. Gunn expressed excitement for Iterative Health's focus on "extending cutting-edge clinical research into the communities that care for these patients." "Iterative Health has created an impressive foundation to advance hepatology and obesity research at scale," Gunn said. Impact Research Institute, which Gunn founded, is recognized as a leading U.S. hepatology research center. Gunn is also a committee member of Women in Hepatology: Initiatives, Sponsorship, and Empowerment within the Chronic Liver Disease Foundation. Her academic resume includes teaching posts at Texas A&M, the University of Texas at Austin, and Baylor University.

Machine Vision & HealthTogether with LLMs (large language models) like ChatGPT, machine vision is one of the most important recent developments in AI. The various methods used to achieve it, such as neural networks and deep learning, are now allowing computers to truly see their environment.One application of this idea is letting computers take over humans' tasks like driving or giving robots full autonomy in the real world instead of staying confined to factory floors.It is one one of the large drivers of machine vision adoption, a quickly growing market expected to reach $9.2B by 2029.But another equally important task is judging our health. Many medical diagnoses rely on doctors' visual assessments. This includes direct examination and expert-level analysis of radiography, scanners, and other medical images.In most cases, these visual inspections are somewhat subjective. A doctor will need many years of experience to become truly confident in his assessment. And until now, the complexity of each patient’s body being slightly different made it too complex for automatized measurement.This is finally changing, and many companies are now exploring deploying AI machine vision to create superior analyses of medical images.Direct Visual ExaminationWe recently explored the case of using AI to detect better than human doctor ear infections in our article “AI Poised to Become Invaluable Medical Diagnosis Tool”This can be expanded to many other pathologies; for example, Google's AI imaging can be used to diagnose 26 different skin diseases (80% of cases seen in primary care), detect diabetic retinopathy , or even predict the risk of developing diabetic retinopathy in the future .More surprisingly, AI also appears to be able to detect health issues from visual inspections that humans could not use; for example, detecting anemia (normally requiring a blood test) from a look at the eye’s retina